Access
To read this article in full you may need to log in, make a payment or gain access through a site license (see right).
Review
Nature Reviews Cancer 6, 130–140 (1 February 2006) | doi:10.1038/nrc1801
Non-steroidal anti-inflammatory drugs for cancer prevention: promise, perils and pharmacogenetics
&
Abstract
Aspirin and other non-steroidal anti-inflammatory drugs (NSAIDs) show indisputable promise as chemopreventive agents. Possible targets include cancers of the colon, stomach, breast and lung. However, recent studies raise concern about potential cardiovascular toxicity associated with the use of NSAIDs that specifically target the enzyme cyclooxygenase 2. These findings, and others that show that inherited genetic characteristics might determine preventive success, argue for new strategies that are tailored to individual medical history and genetic make-up.
To read this article in full you may need to log in, make a payment or gain access through a site license (see right).
